Sera Prognostics, Inc.
SERA
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.82
FAIR PRICE
$2.28
MARGIN
$0.46
P/E Ratio
N/A
Div. Yield
N/A
ROE
-37.5%
Market Cap
$70M
Small-cap
COMING SOON
Get notified when SERA's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Gregory C. Critchfield
COUNTRY
US
HEADQUARTERS
Salt Lake City
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate SERA's fair price
Sera Prognostics, Inc.'s fair price of $2.28 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $1.82, SERA trades 25.3% below its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting SERA's risk profile.
RELATIVE · 30%
Comparing SERA's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for SERA, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for SERA.
Explore on BuliosFAQ
What is the fair price of SERA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Sera Prognostics, Inc. is $2.28. At the current market price of $1.82, SERA trades 25.3% below its calculated fair value.
Is SERA overvalued or undervalued?+
Sera Prognostics, Inc. is currently undervalued based on our valuation model. The stock trades at $1.82, which is 25.3% below the fair price of $2.28.
How often is SERA's fair price updated?+
We update fair price calculations for SERA daily after market close. The current fair price of $2.28 incorporates the latest market data and sector multiples.
What factors affect SERA's fair price calculation?+
SERA's fair price of $2.28 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -37.5%.
Is SERA a good buy right now?+
At $1.82, SERA trades 25.3% below our fair value estimate of $2.28. The stock is currently undervalued. ROE stands at -37.5% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does SERA pay dividends?+
SERA does not currently pay a dividend.